AZD8529 Single Ascending Dose Study

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy Volunteer

In brief

This is a study to evaluate safety, tolerability, PK and PD effects of orally administered AZD8529 after single ascending doses

Key facts

Study ID

NCT00755378

Run by

AstraZeneca

People needed

58

Starts

2008-09-01

Expected to finish

2009-03-01

Last updated by the study team

2009-03-26

Who can join

Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy male or female subjects aged 18 to 45 years (inclusive) on Day 1. Female subjects must be of non-child bearing potential.

You may not qualify if…

• Has received another new chemical entity (defined as a compound which has not been approved for marketing) or has participated in any other clinical study that included drug treatment within 3 months of the first administration of investigational prod
• Plasma donation within one month of screening or any blood donation/blood loss > 500mL during the 3 months prior to screening
• Clinically relevant abnormalities in physical examinations, vital signs, ECG, clinical chemistry, hematology or urinalysis

Where it is running

• Research Site — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.